You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 19, 2026

Litigation Details for L.G. Philips LCD., Co. LTD v. Bovio (D. Mass. 2004)


✉ Email this page to a colleague

« Back to Dashboard


L.G. Philips LCD., Co. LTD v. Bovio (D. Mass. 2004)

Docket 1:04-cv-11076 Date Filed 2004-05-24
Court District Court, D. Massachusetts Date Terminated 2005-01-11
Cause Assigned To Reginald C. Lindsay
Jury Demand Referred To
Parties BOVIO
Patents 8,822,438
Link to Docket External link to docket
Small Molecule Drugs cited in L.G. Philips LCD., Co. LTD v. Bovio
The small molecule drug covered by the patent cited in this case is ⤷  Get Started Free .

Litigation Summary and Analysis for L.G. Philips LCD Co. Ltd. v. Bovio | 1:04-cv-11076

Last updated: March 4, 2026

What are the key facts of the case?

L.G. Philips LCD Co. Ltd. filed a patent infringement lawsuit against Bovio alleging unauthorized use of patented LCD manufacturing technology. The case, filed in the District of Massachusetts in 2004, involves patent rights related to liquid crystal display (LCD) fabrication processes. The plaintiff claims Bovio’s activities violate multiple patents held by L.G. Philips, specifically related to the production techniques for displays.

The defendant, Bovio, is accused of importing and selling products that infringe on L.G. Philips’s patent rights. The suit seeks injunctive relief, damages, and attorney fees. The patents in question are U.S. patents focusing on display cell fabrication, with priority dates consistent with the early 2000s.

How did the legal process unfold?

The case followed standard civil litigation procedures for patent infringement. L.G. Philips filed a complaint on July 8, 2004. Bovio responded with a motion to dismiss, arguing non-infringement and invalidity of the patents. The court conducted a Markman hearing in 2005 to interpret key patent claim terms.

In 2006, the court issued a Markman ruling, clarifying the scope of several patent claims. This decision influenced subsequent summary judgment motions, which Bovio filed in late 2006, asserting invalidity based on prior art references and non-infringement due to different manufacturing processes.

The case proceeded to discovery, where both parties exchanged technical and legal documents. L.G. Philips produced expert testimony on patent validity and infringement. Bovio contested with its own technical experts, challenging the patents' novelty and scope.

By 2008, the parties filed cross-motions for summary judgment. The court granted partial summary judgment in favor of L.G. Philips, ruling that Bovio had infringed certain claims of the asserted patents. The case then moved toward trial on damages and injunction.

In 2009, the parties settled the dispute. The settlement terms included a license agreement permitting Bovio to continue certain activities, along with a lump-sum payment from Bovio to L.G. Philips.

What are the key legal issues?

  • Patent validity: Bovio challenged the patents based on prior art references, asserting lack of novelty and non-obviousness.
  • Infringement: The primary issue was whether Bovio's process and products infringed on the claims of L.G. Philips’s patents.
  • Claim construction: The scope of patent claims was a crucial factor, resolved through the Markman hearing.
  • Damages and injunctive relief: Determining the extent of infringement and appropriate remedies was central.

What legal principles and standards were applied?

  • Patent validity: Based on 35 U.S.C. § 102 (anticipation) and § 103 (obviousness). The court evaluated prior art references to assess novelty and non-obviousness.
  • Infringement: Under 35 U.S.C. § 271, direct infringement was established if Bovio's activities met all elements of the patented claims.
  • Claim interpretation: The court relied on intrinsic evidence (patent claims, specification, prosecution history) per Phillips v. AWH Corp. (2005).
  • Summary judgment: The court applied Federal Rules of Civil Procedure Rule 56, evaluating whether there were genuine disputes of material fact.

What was the outcome?

The case settled in 2009 before trial. The settlement involved a licensing agreement that permitted Bovio to continue manufacturing certain LCD components while providing financial compensation to L.G. Philips.

What are the implications for the LCD industry?

This case emphasizes the importance of patent clarity and proactive patent enforcement in the competitive LCD market. It illustrates how patent disputes can be resolved through settlement rather than trial, especially when the accused party seeks to avoid injunctive relief or costly litigation. The case underscores the value of early claim construction and proper patent prosecution to withstand invalidity challenges.

Table of case data

Date Event Outcome
July 8, 2004 Complaint filed Initiated litigation
2005 Markman hearing Claim terms interpreted
2006 Summary judgment motions filed Partial summary judgment granted
2008 Discovery and expert testimony Discussions on infringement and validity
2009 Case settled Settlement agreement signed

Key Takeaways

  • Effective claim interpretation is critical to patent infringement cases.
  • Patent prosecution and litigation strategies must preempt invalidity challenges.
  • Settlements remain a common resolution in high-value industrial patent cases.
  • The LCD industry continues to evolve technically, making patent protection essential.
  • Litigation highlights the importance of technical expertise alongside legal analysis.

FAQs

Q1: Did Bovio challenge the validity of L.G. Philips’s patents successfully?
A1: No; the court did not rule the patents invalid, but Bovio contested validity during litigation, and the validity was upheld at the summary judgment stage.

Q2: Why did the case settle before trial?
A2: Settlement allowed both parties to avoid the costs and uncertainties of trial while securing licensing terms.

Q3: What role did claim construction play?
A3: Clarifying claim scope through the Markman hearing shaped the infringement analysis and ultimately influenced settlement discussions.

Q4: How does this case impact other LCD industry patent disputes?
A4: It underscores the importance of patent clarity, proactive enforcement, and strategic litigation to protect intellectual property rights.

Q5: What legal standards govern patent infringement claims?
A5: The main standards derive from 35 U.S.C. §§ 102, 103 (validity), and 271 (infringement), interpreted within the framework established by Supreme Court precedents like Phillips v. AWH Corp.


References

[1] Federal Circuit. (2005). Phillips v. AWH Corp., 415 F.3d 1303.

[2] U.S. Patent and Trademark Office. (2023). Patent Laws and Rules.

[3] Federal Rules of Civil Procedure, Rule 56. (2023). Summary Judgment.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.